Loading...
Neumora Therapeutics, Inc. Common Stock
NMRA•NASDAQ
HealthcareBiotechnology
$1.02
$0.21(25.91%)
Neumora Therapeutics, Inc. Common Stock (NMRA) Financial Performance & Statements
Review Neumora Therapeutics, Inc. Common Stock’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
0.00%
Operating Income Growth
-40.00%
↓ 40.00%
Net Income Growth
-3.33%
↓ 3.33%
Operating Cash Flow Growth
-12.04%
↓ 12.04%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-84.79%
↓ 84.79%
ROIC
-120.13%
↓ 120.13%
Neumora Therapeutics, Inc. Common Stock (NMRA) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Neumora Therapeutics, Inc. Common Stock stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $160000.00 | $158000.00 |
| Gross Profit | $0.00 | $0.00 | -$160000.00 | -$158000.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $45.91M | $60.63M | $48.63M | $45.76M |
| SG&A Expenses | $17.01M | $16.02M | $15.19M | $14.32M |
| Operating Expenses | $62.92M | $76.65M | $63.82M | $60.07M |
| Total Costs & Expenses | $62.92M | $76.65M | $63.82M | $60.07M |
| Interest Income | $4.09M | $4.21M | $5.27M | $6.37M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $157000.00 | $156000.00 | $160000.00 | $158000.00 |
| EBITDA | -$62.77M | -$76.49M | -$63.66M | -$59.92M |
| EBITDA Ratio | ||||
| Operating Income | -$62.92M | -$76.65M | -$63.82M | -$60.07M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $4.10M | $4.15M | $5.25M | $6.35M |
| Income Before Tax | -$58.82M | -$72.49M | -$58.58M | -$53.72M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $53000.00 | $125000.00 | -$6.37M |
| Net Income | -$58.82M | -$72.55M | -$58.70M | -$53.72M |
| Net Income Ratio | ||||
| EPS | -$0.37 | -$0.45 | -$0.37 | -$0.34 |
| Diluted EPS | -$0.37 | -$0.45 | -$0.37 | -$0.34 |
| Weighted Avg Shares Outstanding | $160.98M | $159.58M | $158.98M | $157.94M |
| Weighted Avg Shares Outstanding (Diluted) | $160.98M | $159.58M | $158.98M | $157.94M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan